| Business Summary | | Fusion
Medical
Technologies,
Inc.
develops,
manufactures
and
markets
proprietary
surgical
hemostatic
sealant
products.
Hemostatic
products
are
used
to
stop
bleeding
during
surgical
procedures.
The
Company's
primary
commercial
product,
FloSeal
matrix
hemostatic
sealant,
combines
a
gel
derived
from
collagen
with
thrombin,
a
potent
clotting
agent,
to
control
surgical
bleeding.
FloSeal
is
designed
to
complement
sutures
and
staples
and
to
overcome
limitations
of
other
existing
products
used
to
control
bleeding,
including
topical
hemostats,
fibrin
glues
and
other
types
of
surgical
sealants
and
adhesives. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Fusion
Medical
Technologies
is
developing
and
commercializing
proprietary
collagen-based
flowable-gel
products
used
to
control
bleeding
in
a
variety
of
surgeries.
For
the
six
months
ended
6/30/01,
revenues
totaled
$5.2
million,
up
from
$1.8
million.
Net
loss
rose
18%
to
$7.5
million.
Revenues
reflect
increased
usage
of
FloSeal
by
doctors
and
hospitals.
Net
loss
reflects
higher
sales
and
marketing
expenses
due
to
personnel
costs
of
the
Company's
direct
sales
force. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Gordon Russell, 67 Chairman | -- | Philip Sawyer, 36 Pres,
CEO | $220K | Larry Strauss, 48 CFO,
VP-Fin. | -- | Scott Huie, 42 VP,
Operations | 183K | Dan Ellis, 49 VP
of Sales | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|